Q1 Pathophysiology and management of central line associated bloodstream infection. Q2 Neuropathic claudication pain management. Q3 Nosocomial infection in ICU AND ANTICOAGULANT IN ICU. answer rhese quewtion for 10 marks each as per DNB anesthesia final exam with standard sources aa refrence

Reading File

Finding Sources

Reading File

Searching PubMed

"central line associated bloodstream infection" prevention management

Searching PubMed

"neurogenic claudication" treatment management

DNB Anaesthesia Final Examination Answers

Q1. Pathophysiology and Management of Central Line Associated Bloodstream Infection (CLABSI) [10 Marks]

Definition and Terminology

CLABSI (Central Line-Associated Bloodstream Infection) is a laboratory-confirmed bloodstream infection in a patient with a central venous catheter (CVC) in place for at least 48 hours before onset, with no other identifiable source. It is a surveillance definition used by the CDC.

CRBSI (Catheter-Related Bloodstream Infection) is the clinical diagnosis used for treatment decisions. It requires specific laboratory criteria to confirm the catheter as the source (catheter-tip culture, quantitative blood cultures, or differential time to positivity).

CLABSI carries a 15% mortality rate and an odds ratio of 2.75 for death. In 2019, 18,009 CLABSIs were reported across US hospitals. Since 2008, CMS no longer reimburses hospitals for CLABSI as it is classified a preventable complication.

Pathophysiology

The central mechanism is migration of skin flora along the external catheter surface or intraluminally, colonizing the catheter tip, and then gaining access to the bloodstream.

Four routes of catheter contamination:

Extraluminal (skin flora migration) - The most common route for short-term catheters. Organisms colonize the insertion site and track along the outer surface of the catheter to the tip.
Intraluminal (hub contamination) - More important in long-term catheters. Organisms are introduced via the catheter hub during access, travel along the inner lumen.
Hematogenous seeding - From a distant site of infection; organisms seed the catheter biofilm.
Infusate contamination - Rarely, contaminated fluids introduced directly.

Biofilm formation is the key pathophysiological step. Once organisms adhere to the catheter surface (facilitated by host proteins such as fibrin, fibronectin, and albumin coating the catheter), they form a biofilm that is highly resistant to antibiotics and host immune defenses. Tunneled catheters have a subcutaneous cuff that creates a physical barrier to bacterial migration, making them less prone to extraluminal infection.

Common organisms:

Coagulase-negative Staphylococcus (most common)
Staphylococcus aureus (most virulent; highest risk of seeding)
Gram-negative bacilli (Klebsiella, Pseudomonas, Enterobacter)
Enterococcus
Candida spp. (especially in immunocompromised and TPN patients)

Diagnosis

Suspect CRBSI in any patient with a CVC exhibiting fever, rigors, hypotension, tachycardia, altered mental status, or lactic acidemia without another source.

Clinical assessment:

Inspect catheter site for erythema, purulent discharge, tenderness
Evaluate for complications: endocarditis, septic thrombophlebitis, metastatic musculoskeletal infection

Microbiological criteria (IDSA 2009 Guidelines):

Method	Criteria
Quantitative catheter tip + peripheral blood culture	Same organism from both sites
Quantitative blood cultures	3-fold higher colony count from catheter vs. peripheral blood
Differential time to positivity (DTP)	Catheter blood culture positive ≥2 hours before peripheral sample
Dual-lumen quantitative	≥3-fold colony count difference between two catheter lumens

Obtain two sets of peripheral blood cultures from separate venipuncture sites before starting antibiotics.

Management

A. Empiric Antibiotic Therapy

Start after blood cultures are drawn in hemodynamically unstable patients; may be delayed in stable patients awaiting cultures.

Vancomycin (IV) - empiric first choice to cover MRSA and coagulase-negative staphylococci; adjust dose to trough level 15-20 mcg/mL or AUC-guided dosing
Add gram-negative coverage (piperacillin-tazobactam, cefepime, or a carbapenem) in immunocompromised, severely ill, or known GNB-colonized patients
Add antifungal (echinocandin: micafungin or caspofungin) if candidemia suspected (TPN, prolonged antibiotics, hematological malignancy)

B. Definitive Therapy Based on Organism

Organism	Antibiotic	Duration
MRSA	Vancomycin or daptomycin	14 days from first negative culture
MSSA	Nafcillin or oxacillin (or cefazolin)	14 days
Coag-negative staphylococci	Vancomycin	5-7 days (if catheter removed)
Gram-negative bacilli	Beta-lactam per sensitivity	7-14 days
Candida	Echinocandin, then fluconazole step-down	14 days from first negative culture; ophthalmology review mandatory

S. aureus bacteremia mandates echocardiography to exclude endocarditis and a minimum of 14 days therapy from the first negative blood culture.

C. Catheter Management

Remove immediately in:

Severe sepsis / septic shock
Complicated CRBSI (endocarditis, septic thrombophlebitis)
Persistent bacteremia >72 hours despite appropriate antibiotics
Infection with S. aureus, MDR gram-negatives, mycobacteria, fungi

Catheter salvage (antimicrobial lock therapy) may be attempted only in:

Patients with very limited venous access
Long-term catheters (ports, tunneled lines)
Infection with coagulase-negative staphylococci or gram-negatives (not S. aureus or fungi)
Requires serial surveillance cultures every 24 hours; remove if bacteremia persists beyond 72 hours

Antimicrobial lock therapy = highly concentrated antibiotic + anticoagulant instilled into the catheter lumen and allowed to dwell.

Prevention - The CLABSI Bundle

Insertion Bundle:

Element	Recommendation
Hand hygiene	Before and after every patient contact
Maximal sterile barrier precautions	Sterile gown, gloves, cap, mask, large sterile drape
Skin antisepsis	Chlorhexidine gluconate >0.5% in alcohol (preferred); povidone-iodine if CHG sensitive
Catheter site selection	Subclavian < internal jugular < femoral (risk order)
Minimum ports	Use catheter with fewest lumens necessary
Antimicrobial-impregnated catheters	Consider if prolonged use expected

Maintenance Bundle:

Daily review of catheter necessity; remove at earliest
Chlorhexidine-impregnated dressings
Aseptic technique for every hub access
Dedicated phlebotomy team (reduces contamination)
Scheduled replacement of catheters does NOT reduce CLABSI

Healthcare provider education is the cornerstone of prevention. The national CLABSI rate in the US decreased 46% from 2008-2013 with bundle implementation.

References: Sabiston Textbook of Surgery, 21e (Chapter on Surgical Complications); Current Surgical Therapy, 14e (Chapter on CLABSI); Harrison's Principles of Internal Medicine, 22e; IDSA Clinical Practice Guidelines 2009.

Q2. Neuropathic Claudication - Pain Management [10 Marks]

Definition

Neurogenic (neuropathic) claudication, also called pseudoclaudication, is leg pain (and often back pain) provoked by walking and relieved by rest and forward flexion. It is caused by dynamic compression of the cauda equina or lumbar nerve roots in the setting of lumbar spinal stenosis, typically at L4-5 (92%) and L3-4 (66%).

It must be distinguished from vascular claudication:

Feature	Neurogenic Claudication	Vascular Claudication
Relief position	Sitting, forward flexion (shopping cart sign)	Standing still sufficient
Provocative posture	Extension of spine	Exertion regardless of posture
Peripheral pulses	Normal	Diminished
ABI	Normal	Reduced
Walking distance	Variable; uphill easier than downhill	Consistent (claudication distance)
Neurological signs	May have motor/sensory deficits	Absent

Neurogenic claudication has a sensitivity of 88% (95% CI 78-98%) for lumbar spinal stenosis. The most common levels are L4-5 and L3-4, with multilevel involvement common. Symptoms include wide-based gait, poor balance, worsened pain with lumbar extension.

Pathophysiology of Pain

The pain in neurogenic claudication is multifactorial:

Mechanical compression of the cauda equina and nerve roots - due to combinations of bulging disk, facet joint hypertrophy, spondylolisthesis, and ligamentum flavum hypertrophy/buckling
Ischemia of nerve roots - walking increases metabolic demand; the compressed nerve roots have impaired microvascular flow (venous congestion model), causing relative ischemia
Neuroinflammation - mechanical compression triggers cytokine release (TNF-alpha, IL-1), sensitizing nociceptors (peripheral sensitization)
Central sensitization - chronic compression leads to wind-up and central sensitization at the dorsal horn level, producing the neuropathic character of the pain

The forward-flexion relief mechanism results from increased spinal canal diameter with flexion (extends the canal ~10-12% in flexion vs. extension), decompressing the neural elements.

Pain Management

Step 1: Conservative (Non-operative) Management

Conservative management is successful in most patients initially. Patients with radicular pain respond particularly well.

A. Physiotherapy and Posture

Flexion-based exercises (Williams' flexion exercises) - maintain forward-bent posture to widen canal
Lumbar stabilization exercises to strengthen paravertebral and core muscles
Aquatic therapy - excellent as water allows flexed-spine ambulation
Use of walking aids, shopping trolley walking (classic flexed posture)
Cycling (preferred over walking - maintains flexed position)
Avoid lumbar extension activities

B. Pharmacological Management

Drug Class	Agent	Mechanism	Evidence
First-line neuropathic	Gabapentin 300-1800 mg/day (titrated)	Binds voltage-gated Ca2+ channels (alpha-2-delta subunit); reduces presynaptic neurotransmitter release	First-line; improves walking distance
First-line neuropathic	Pregabalin 150-600 mg/day	Same mechanism as gabapentin; more predictable pharmacokinetics	First-line; equivalent efficacy
Tricyclic antidepressants	Amitriptyline 10-75 mg nocte	Norepinephrine/serotonin reuptake inhibition; Na+ channel blockade	Useful; sedation aids sleep disruption
SNRI	Duloxetine 60 mg/day	Descending inhibitory pain pathway modulation	Evidence for neuropathic pain; less for claudication specifically
Opioids	Tramadol 50-100 mg QID	Weak opioid + SNRI; modulates descending pathways	Short-term use only; caution in elderly
NSAIDs	Naproxen, diclofenac	Anti-inflammatory; COX inhibition	Limited role; adjunct for inflammatory component
Calcitonin	Salmon calcitonin (nasal)	Reduces spinal cord excitability; opioid-sparing mechanism	Some evidence for claudication distance improvement
Prostaglandins	Lipo-PGE1 (limaprost)	Improves microcirculation; analgesic	Used in Japan; some RCT evidence

C. Interventional Pain Management

Caudal/Lumbar Epidural Steroid Injections (ESI)
- Reduces perineural inflammation (decreases TNF-alpha and inflammatory cytokines)
- Provides short-to-medium term relief (weeks to months)
- Transforaminal approach (TFESI) delivers steroid closer to the target nerve root - preferred for radicular component
- Interlaminar ESI for central stenosis
- Not disease-modifying; effects are temporary (repeat at 3-month intervals, max 3 per year)
- Complications: post-dural puncture headache, infection, epidural hematoma, rare cord infarction (transforaminal)
Nerve Root Blocks (Selective)
- Target specific compressed nerve root under fluoroscopy/CT guidance
- Both diagnostic and therapeutic
Intrathecal Drug Delivery (Spinal Cord Stimulation)
- Reserved for refractory cases; modulates pain at dorsal horn level
- Spinal cord stimulation (SCS) - dorsal column stimulation
- Intrathecal opioids or baclofen for severe, refractory pain
Adhesiolysis (Racz Procedure)
- Percutaneous epidural adhesiolysis to lyse epidural adhesions contributing to compression

D. Multimodal Approach A combined approach of physiotherapy + gabapentinoid + ESI is the standard of care before considering surgery.

Step 2: Surgical Management (for refractory cases)

Indications: failure of conservative treatment for 6-12 weeks, progressive neurological deficit, severe disability, or cauda equina syndrome.

Decompressive laminectomy - gold standard for multilevel central stenosis
Microsurgical decompression - bilateral decompression via unilateral approach (BDUL) - preserves spinal stability
Minimally invasive decompression (MIS) - reduces recovery time
Interspinous process devices (IPD, e.g., X-Stop) - for patients unfit for surgery; maintain flexion
Lumbar fusion (PLIF, TLIF) - added if spondylolisthesis or instability is present

Surgical outcomes are good in carefully selected patients - approximately 65-75% report significant improvement at 2 years.

Step 3: Anesthetic Considerations in Neurogenic Claudication

Neuraxial anaesthesia for patients presenting for surgery: note pre-existing neurological deficits and document carefully
Position patients carefully (flexion-neutral preferred); extension on OR table can worsen symptoms
Multimodal analgesia post-operatively: gabapentin + paracetamol + NSAIDs + low-dose opioid

References: Harrison's Principles of Internal Medicine, 22e (Radicular Pain, Spinal Stenosis); Schwartz's Principles of Surgery, 11e; Miller's Review of Orthopaedics, 9e; Campbell's Operative Orthopaedics, 15e; Tintinalli's Emergency Medicine (Spinal Stenosis); Textbook of Family Medicine, 9e

Q3. Nosocomial Infections in ICU AND Anticoagulation in ICU [10 Marks]

PART A: Nosocomial Infections in ICU (5 Marks)

Definition

A nosocomial (hospital-acquired) infection is an infection originating in a patient while in hospital that was neither present nor incubating at the time of admission. Infections occurring >48 hours after admission are classified as nosocomial.

ICU patients are disproportionately affected due to: severe immunocompromise, invasive procedures and devices, prolonged hospitalization, and intensive antibiotic pressure selecting resistant organisms.

Common ICU Nosocomial Infections

Infection	Causative Organisms	Device/Risk Factor
VAP (Ventilator-Associated Pneumonia)	Early: oropharyngeal flora (H. influenzae, S. pneumoniae); Late: MDR (Pseudomonas, MRSA, Acinetobacter, Klebsiella)	Mechanical ventilation >48 hours
CLABSI	CoNS, S. aureus, GNB, Candida	Central venous catheter
CAUTI (Catheter-Associated UTI)	E. coli, Klebsiella, Enterococcus, Candida	Urinary catheter; most common nosocomial infection
CRAB/CRKP	Acinetobacter baumannii, Klebsiella pneumoniae (carbapenem-resistant)	Prolonged ICU stay, prior antibiotics
CDI (C. difficile Infection)	Clostridioides difficile	Antibiotic use, PPIs
Surgical Site Infection (SSI)	S. aureus, GNB	Post-surgical patients

Pathophysiology of Nosocomial Infection in ICU

Sources (triad):

Patient - endogenous flora, skin breakdown, gut translocation
Staff - hands are the most common vector of transmission; nasal MRSA carriage
Environment - contaminated equipment, surfaces, air (especially in immunocompromised units)

Routes of spread:

Direct contact (hands of healthcare workers) - most important
Droplet infection
Airborne particles
Invasive devices creating direct entry points bypassing natural defenses

Host factors predisposing ICU patients:

Immunosuppression (corticosteroids, chemotherapy, diabetes, renal failure)
Breach of skin/mucosal barriers (endotracheal tubes, CVCs, urinary catheters)
Loss of normal microbiome (broad-spectrum antibiotics)
Malnutrition and hyperglycemia (impaired neutrophil function)

Specific ICU Nosocomial Infections

1. Ventilator-Associated Pneumonia (VAP)

Defined as pneumonia after ≥2 days of mechanical ventilation
Criteria: worsening oxygenation + purulent secretions + new CXR infiltrate + positive culture
Early-onset VAP (<4 days): oropharyngeal organisms
Late-onset VAP (≥5 days): MDR pathogens
Treatment: 7 days of targeted antibiotics (equivalent outcomes to 14-day courses)

VAP Prevention Bundle (Institute for Healthcare Improvement):

Head-of-bed elevation 30-45 degrees
Daily sedation vacation + spontaneous breathing trial (SBT)
Oral chlorhexidine decontamination
Subglottic suction (hi-volume suctioning of secretions above cuff)
DVT and peptic ulcer prophylaxis
Implementation reduces VAP rates and mortality

2. CAUTI - most common nosocomial infection overall; prevent by early catheter removal and aseptic placement

3. CLABSI - (detailed in Q1 above)

Prevention of Nosocomial Infections in ICU

Strategy	Implementation
Hand hygiene	WHO "5 moments"; alcohol-based handrub; cornerstone of prevention
Contact precautions	Gown + gloves for MDR organism-colonized patients
Care bundles	VAP bundle, CLABSI bundle, CAUTI bundle
Antibiotic stewardship	De-escalation, shortest effective courses, culture-guided therapy
Surveillance	Active surveillance cultures for MRSA, VRE, CRE
Environmental decontamination	UV-C robots, enhanced terminal cleaning
Isolation	Patients with MDR organisms in single rooms
Selective Decontamination of Digestive Tract (SDD)	Oral + enteral antibiotics ± IV cefotaxime in certain ICU settings

PART B: Anticoagulation in ICU (5 Marks)

Why Anticoagulation Matters in the ICU

ICU patients face a dual paradox: they are simultaneously at high risk for venous thromboembolism (VTE) (due to immobility, endothelial injury, hypercoagulability from critical illness) and at high risk for bleeding (due to coagulopathy, thrombocytopenia, active hemorrhage, or recent procedures).

1. VTE Prophylaxis (Thromboprophylaxis)

All ICU patients are at high risk for DVT due to immobility. All should receive prophylaxis unless contraindicated.

Options:

Method	Agent/Dose	Notes
LMWH (preferred)	Enoxaparin 40 mg SC daily (CrCl >30); 20 mg SC daily if CrCl <30	More effective than UFH; lower HIT risk; anti-Xa monitoring in renal impairment
Unfractionated heparin (UFH)	5000 units SC BD/TDS	Use when LMWH contraindicated (renal failure); easily reversed with protamine
Mechanical	Sequential compression devices (SCDs), graduated compression stockings	Use when anticoagulation contraindicated (active bleeding, thrombocytopenia)
Combined	UFH/LMWH + SCD	Observational studies show concerning DVT incidence even with standard prophylaxis alone

LMWH vs. UFH:

LMWH (enoxaparin) is more effective than UFH for DVT prophylaxis in high-risk patients
LMWH has lower incidence of HIT (Heparin-Induced Thrombocytopenia) - but renal clearance limits use in AKI
UFH preferred in severe renal failure (CrCl <15-20 mL/min) as it is renally independent

HIT in ICU: Heparin prophylaxis may cause HIT (type II), another nosocomial complication in critically ill patients. Suspect when platelet count drops >50% from baseline or falls below 100,000 after 5-10 days of heparin. If HIT suspected: STOP all heparin, use argatroban or fondaparinux as alternative.

2. Therapeutic Anticoagulation in ICU

Indicated for:

Confirmed DVT or pulmonary embolism
Atrial fibrillation with high CHADS2-VASc score
Mechanical heart valves
Arterial or venous thrombosis complicating critical illness

Therapeutic options:

Agent	Route	Mechanism	Monitoring	ICU Consideration
UFH infusion	IV	Anti-Xa + anti-IIa	aPTT 60-100 sec (1.5-2x normal)	Preferred for acute PE/DVT; easily reversed; use in renal failure
LMWH (enoxaparin 1 mg/kg SC BD)	SC	Mainly anti-Xa	Anti-Xa levels (0.6-1.0 IU/mL) if renal impairment	Avoid in severe renal failure
Fondaparinux	SC	Anti-Xa only	Anti-Xa	HIT alternative; avoid in CrCl <30
Argatroban	IV	Direct thrombin inhibitor	aPTT or ACT	Drug of choice for HIT in ICU; hepatic metabolism
Bivalirudin	IV	Direct thrombin inhibitor	ACT or aPTT	Used in PCI; renal/hepatic independent
DOACs (rivaroxaban, apixaban)	PO	Anti-Xa / anti-IIa	None routinely	Limited role in acute ICU phase; use once patient stable and enteral route available
Warfarin	PO	Vitamin K antagonist	INR 2-3	Difficult to titrate in ICU; drug interactions; transition agent

3. Anticoagulation in Special ICU Scenarios

Renal Replacement Therapy (CRRT):

Regional citrate anticoagulation is preferred (anticoagulates only the circuit, not the patient)
Systemic heparin used as alternative in low bleeding risk
Citrate chelates ionized calcium in the circuit; calcium is replaced systemically
Meta-analyses favor citrate over heparin for circuit patency and reduced bleeding

COVID-19 in ICU:

A multiplatform RCT (ATTACC/ACTIV-4a/REMAP-CAP) showed therapeutic-dose heparin improved survival in non-critically ill hospitalized COVID-19 patients
In critically ill COVID-19 ICU patients, therapeutic-dose anticoagulation did not improve survival vs. standard prophylaxis and increased bleeding risk
Therefore: critically ill COVID-19 = standard thromboprophylaxis (not therapeutic anticoagulation) unless specific VTE indication

Monitoring and Reversal:

UFH: aPTT; reversed by protamine (1 mg per 100 units UFH)
LMWH: anti-Xa; partially reversed by protamine
Warfarin: INR; reversed by Vitamin K + 4-factor PCC (prothrombin complex concentrate) or FFP
DOACs: Idarucizumab reverses dabigatran; Andexanet alfa reverses factor Xa inhibitors
Argatroban: aPTT; no specific antidote (short half-life, just stop infusion)

Balancing Risks in the ICU

Condition	Anticoagulation Decision
Active intracranial hemorrhage	Contraindicated; mechanical only
Post-neurosurgery <24 hours	Mechanical only; start chemical after 24-48 hours
Active GI bleed	Mechanical; address bleeding source first
Thrombocytopenia (platelet <50,000)	Hold chemical; mechanical prophylaxis
Acute liver failure (INR elevated)	Patient may appear "auto-anticoagulated" but is NOT - thrombin generation can be paradoxically preserved; individual risk assessment

References:

Harrison's Principles of Internal Medicine, 22e (Critical Care Medicine; DVT in ICU)

Sabiston Textbook of Surgery, 21e (Nosocomial Infections; VAP; CLABSI)

Braunwald's Heart Disease, 15e (Anticoagulation Strategies; COVID-19)

Current Surgical Therapy, 14e (CLABSI and Catheter Care Bundles)

Park's Textbook of Preventive and Social Medicine, 26e (Nosocomial Infections)

Brenner & Rector's The Kidney, 10e (CRRT anticoagulation: citrate vs. heparin)

IDSA Clinical Practice Guidelines (2009) for CRBSI

CDC/NHSN Surveillance Definitions

ATTACC/ACTIV-4a/REMAP-CAP trial (therapeutic heparin in COVID-19)

Exam tip for DNB: Each question should have a clear introduction (1 mark), pathophysiology/mechanism (3 marks), management with tables/classification (5 marks), and prevention/current guidelines (1 mark). Draw diagrams wherever possible - the CLABSI routes of contamination diagram and VAP bundle checklist are commonly expected.

Q3. Nosocomial Infections in ICU AND Anticoagulation in ICU [10 Marks]

Finding Sources

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

This is a shared conversation. Sign in to Orris to start your own chat.